Merck & Co Inc
6MK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
75,000
Stocks News & Analysis
stocks
ASX healthcare giant rallies despite a fall in profits
Easing investor concerns and signalling a return to growth.
stocks
Weekly earnings wrap: BHP, CSL, NAB and more
Materials, banking, healthcare and retail heavyweights reveal diverging outlooks.
stocks
Chart of the Week: Our top dividend stock picks on the ASX
Highlighting key income opportunities on the ASX.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,290.10 | 18.00 | -0.19% |
| CAC 40 | 8,501.91 | 7.45 | -0.09% |
| DAX 40 | 26,091.33 | 37.03 | -0.14% |
| Dow JONES (US) | 53,463.05 | 119.65 | 0.22% |
| FTSE 100 | 10,743.35 | 15.31 | 0.14% |
| HKSE | 25,776.45 | 281.38 | 1.10% |
| NASDAQ | 26,331.09 | 41.38 | 0.16% |
| Nikkei 225 | 66,122.12 | 795.70 | 1.22% |
| NZX 50 Index | 13,919.82 | 9.85 | -0.07% |
| S&P 500 | 7,707.98 | 16.22 | 0.21% |
| S&P/ASX 200 | 9,074.90 | 26.90 | -0.30% |
| SSE Composite Index | 3,890.94 | 3.49 | -0.09% |